Bruno Stricker, MB PhD
| || |
Bruno HCh Stricker finished his medical school at the University of Leiden in 1977 and did a PhD thesis in hepatology at Erasmus University Medical School in Rotterdam in 1987. Since 1991, he is both head of the Drug Safety Unit of the Inspectorate for Health Care, and head of the Pharmaco-epidemiology Unit of the Department of Epidemiology of the Erasmus University Medical School. Here, he was appointed professor of pharmacoepidemiology in 2001.
Bleumink GS, Feenstra J, Sturkenboom MCJM, Stricker BHCh. Nonsteroidal anti-inflammatory drugs and heart failure. Drugs 2003;63:525-34.
Beiderbeck AB, Holly EA, Sturkenboom MCJM, Coebergh JW, Stricker BHCh, Leufkens HGM. Prescription medications associated with a decreased risk of non-Nodgkin's lymphoma. Am J Epidemiol 2003;157:510-16.
Leeuwen R van, Vingerling JR, Hofman A, Jong PTVM de, Stricker BHCh. Cholesterol lowering drugs and risk of age related maculopathy: prospective cohort study with cumulative exposure measurement. BMJ 2003;326:255-6.
Beiderbeck-Noll AB, Sturken MCJM, Linden PD van der, Herings RMC, Hofman A, Coebergh JWW, Leukens HGM, Stricker BHCh. Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam Study. Eur J Cancer 2003;39:98-105.
Maitland-van der Zee AH, Stricker BHCh, Klungel OH, Kastelein JJ, Hofman A, Witteman JC, Breteler MMB, Leufkens HGM, Duijn CM van, Boer A de. The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors in the elderly is not influenced by apoliprotein E genotype. Pharmacogenetics 2002;8:647-53.
Visser LE, Penning-van Beest FJA, Kasbergen HAA, Smet PAGM de, Vulto AG, Hofman A, Stricker BHCh. Overanticoagulation associated with combined use of antibacterial agents and acenocoumarol or phenprocoumon anticoagulants. Thromb Haemost 2002;88:705-10.
Riemsdijk MM van, Sturkenboom MCJM, Ditters JM, Ligthelm RJ, Overbosch D, Stricker BHCh. Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: A focus on neuropsychiatric adverse events. Clin Pharmacol Ther 2002;72:294-301.
Dieleman JP, Sturkenboom MCJM, Jambroes M, Gyssens IC, Weverling GJ, Veen JH ten, Schrey G, Reiss P, Stricker BHCh, for the ATHENA Study Group. Risk factors for urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: the Athena Cohort. Arch Intern Med 2002;162:1493-1501.
Visser LE, Penning-van Beest FJA, Kasbergen HAA, Smet PAGM de, Vulto AG, Hofman A, Stricker BHCh. Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants. Clin Pharmacol Ther 2002;71:496-502.
't Jong GW, Eland IA, Sturkenboom MCJM, Anker JN van der, Stricker BHCh. Unlicensed and off label prescription of drugs to children: population based cohort study. Br Med J 2002;324:1313-4.
Stricker BHCh, Hofman A, Breteler MMB. Nonsteroidal drugs and Alzheimer's disease.
N Engl J Med 2002;346:1171-3.
Linden PD van der, Sturkenboom MCJM, Hering RMC, Leufkens HGM, Stricker BHCh. Fluoroquinolones and risk of Achilles tendon disorders: case-controle study. Br Med J 2002;324:1306-7.
Dieleman JP, Jambroes M, Gyssens IC, Sturkenboom MC, Stricker BHCh, Mulder WM, Wolf F de, Weverling GJ, Lange JM, Reiss P, Brinkman K. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA Cohort. AIDS 2002;16:737-45.
Feenstra J, Heerdink ER, Grobbee DE, Stricker BHCh. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure.
Arch Int Med 2002;162:265-70.
Veld BA in 't, Ruitenberg A, Hofman A, Launer LJ, Duijn CM van, Stijnen Th, Breteler MMB, Stricker BHCh. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease.
N Engl J Med 2001;345:1515-21.
Penning-van Beest FJ, Meegen E van, Rosendaal FR, Stricker BHCh. Characteristics of anticoagulant therapy and comorbidity related to overcoagulation. Thromb Haemost 2001;86:569-74.
Linden PD van der, Puijenbroek EP van, Feenstra J, Veld BA in 't, Sturkenboom MCJM, Heerings RMC, Leufkens HGM, Stricker BHCh. Tendon disorders attributed to fluoroquinolones: a study of spontaneous reports in the period 1988 to 1998. Arthritis Rheum 2001;45:2350-9.
Penning-van Beest FJ, Meegen E van, Rosendaal FR, Stricker BHCh. Drug interactions as a cuase of overanticoagulation on phenprocoumon ofr acenocoumarol predominantly concern antibacterial drugs. Clin Pharmacol Ther 2001;69:451-7.
Veld BA in 't, Ruitenberg A, Hofman A, Stricker BHCh, Breteler MMB. Antihypertensive drugs and incidence of dementia: the Rotterdam Study. Neurobiol Aging 2001;22:407-12.
Feenstra J, Grobbee DE, Veld BA in 't, Stricker BHCh. Confouding by contraindication in a nationwide cohort study risk for death in patients taking ibopamine. Ann Intern Med 2001;134:569-72.
Dr Stricker has a special interest in drug safety research and other etiological pharmacological aspects. He is in charge of several drug-related research projects in the Rotterdam Study, a large prospective cohort study that is being conducted since 1990 to investigate cardiovascular, locomotor, neurological, and ophthalmological diseases. Apart from that he is heading a couple of nationwide pharmaco-epidemiological field studies.